PSTX241220C5000
- 4.30
- 0.000.00%
Poseida Therapeutics Newsroom
Piper Sandler Maintains Poseida Therapeutics(PSTX.US) With Hold Rating, Maintains Target Price $10
Piper Sandler Downgrades Poseida Therapeutics(PSTX.US) to Hold Rating, Maintains Target Price $10
Roche's Acquisition Offer Leads to Hold Rating for Poseida Therapeutics Amid Promising Pipeline and Financial Uncertainties
A Quick Look at Today's Ratings for Poseida Therapeutics(PSTX.US), With a Forecast Between $9 to $9
Poseida Therapeutics Cut to Market Perform From Outperform by William Blair
Poseida Therapeutics Analyst Ratings
Cantor Fitzgerald Downgrades Poseida Therapeutics(PSTX.US) to Hold Rating
BTIG Downgrades Poseida Therapeutics(PSTX.US) to Hold Rating
Poseida Therapeutics (PSTX) Was Downgraded to a Hold Rating at BTIG
Piper Sandler Maintains Poseida Therapeutics(PSTX.US) With Buy Rating, Maintains Target Price $10
Poseida Therapeutics Analyst Ratings
Poseida Therapeutics (PSTX) Receives a Buy From Piper Sandler
H.C. Wainwright Maintains Poseida Therapeutics(PSTX.US) With Buy Rating, Maintains Target Price $20
William Blair Maintains Poseida Therapeutics(PSTX.US) With Buy Rating
Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Poseida Therapeutics (PSTX) and Evolus (EOLS)
H.C. Wainwright Maintains Poseida Therapeutics(PSTX.US) With Buy Rating, Maintains Target Price $20
William Blair Maintains Poseida Therapeutics(PSTX.US) With Buy Rating
Poseida Therapeutics' Robust Financial Performance and Strategic Collaborations Justify Buy Rating
H.C. Wainwright Maintains Poseida Therapeutics(PSTX.US) With Buy Rating, Maintains Target Price $20
William Blair Maintains Poseida Therapeutics(PSTX.US) With Buy Rating